{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T04:42:49Z","timestamp":1774240969596,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T00:00:00Z","timestamp":1483142400000},"content-version":"vor","delay-in-days":457,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.nrl.2014.09.001","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T03:32:33Z","timestamp":1415676753000},"page":"461-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evaluaci\u00f3n del uso de rituximab en la neuromielitis \u00f3ptica"],"prefix":"10.1016","volume":"30","author":[{"given":"M.J.","family":"Fern\u00e1ndez-Meg\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Casanova-Estruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"P\u00e9rez-Miralles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ruiz-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Alcal\u00e1-Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Poveda-Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2014.09.001_bib0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.33588\/rn.5105.2010268","article-title":"Neuromielitis \u00f3ptica: actualizaci\u00f3n cl\u00ednica","volume":"51","author":"Chiquete","year":"2010","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrl.2014.09.001_bib0010","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2014.09.001_bib0015","unstructured":"Eisen A, Aminoff MJ, Wilterdink JL. Disorders affecting the spinal cord. UpToDate. 2012 [consultado 10 de mayo 2014]. Disponible en: http:\/\/www.uptodate.com\/"},{"key":"10.1016\/j.nrl.2014.09.001_bib0020","first-page":"24","article-title":"Rituximab en el tratamiento de las enfermedades glomerulares","volume":"2","author":"Fern\u00e1ndez-Fresnedo","year":"2009","journal-title":"NefroPlus"},{"key":"10.1016\/j.nrl.2014.09.001_bib0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1756285609356135","article-title":"Practical considerations on the use of rituximab in autoimmune neurological disorders","volume":"3","author":"Kosmidis","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nrl.2014.09.001_bib0030","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2014.09.001_bib0035","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national register (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nrl.2014.09.001_bib0040","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2014.09.001_bib0045","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2014.09.001_bib0050","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nrl.2014.09.001_bib0055","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nrl.2014.09.001_bib0060","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2014.09.001_bib0065","first-page":"110","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"1","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nrl.2014.09.001_bib0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrl.2014.09.001_bib0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pathophys.2010.04.008","article-title":"Neuromyelitis optica and optic spinal multiple sclerosis: Mechanisms and pathogenesis","volume":"18","author":"Kira","year":"2011","journal-title":"Pathophysiology."}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485314001789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485314001789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:34:49Z","timestamp":1747154089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485314001789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0213485314001789"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2014.09.001","relation":{},"ISSN":["0213-4853"],"issn-type":[{"value":"0213-4853","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluaci\u00f3n del uso de rituximab en la neuromielitis \u00f3ptica","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2014.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}